The case for & against
Bull & Bear analysis
ADMA Biologics, Inc. (NASDAQ: ADMA) is a leading provider of specialty plasma-derived biologics with a focus on immunoglobulin therapies for patients suffering from primary immunodeficiency (PI). Its flagship product, Ascentive, aims to offer better clinical outcomes for patients inadequately managed by traditional therapies. The company stands out in the biopharmaceutical industry due to its operational discipline, manufacturing efficiencies, and strategic focus on patient-centric solutions. Given its engaged pipeline, including the SG-001 hyperimmune globulin program, ADMA is positioned to expand its market footprint within the specialty pharmaceuticals realm.
Bull says
- ↑Ascentive drove total revenue to $124.4M (+2% YoY) with 24% growth
- ↑Gross margin rose to 69% (from 55%), and adjusted EBITDA climbed 22% to $61.8M
- ↑Repurchased 13.8M shares (5.3% of float), bolstering EPS and returns
- ↑Reiterated 2026 revenue guidance of $530–$560M; consensus EPS $0.78
- ↑SG-001 hyperimmune program could add $300–$500M in annual sales
- ↑Strong profitability factors and high earnings yield underline value
Bear says
- ↓Increased supply and pricing pressure may compress immunoglobulin margins
- ↓Ascentive growth dependent on physician adoption; slower uptake risks guidance
- ↓Negative book-to-price and dividend yield reflect valuation concerns
- ↓Payer reimbursement shifts could restrict treatment access and sales
- ↓SG-001 regulatory path risks may delay multi-hundred-million‐dollar revenue
- ↓High share volatility and low institutional support increase downside risk
Investment themes with ADMA
Genetic and drug innovations driving medical breakthroughs
Earnings Call · Q1 2024 · Mgmt. Guidance
Transcript signals
Bull points
- Total revenues were $81.9 million for the quarter ended March 31, 2024, as compared to $56.9 million for the first quarter ended March 31, 2023, an increase of $25 million, or approximately 44%.
- Gross profit for the three months ended March 31, 2024 was $39.1 million, as compared to $16.5 million for the same period of a year ago which represents an increase of $22.6 million.
- As a result, ADMA achieved a corporate gross margin of approximately 48% in the first quarter of 2024 as compared to approximately 29% in the first quarter of 2023.